IRL1117 / IRLAB Therap - LARVOL DELTA

IRLAB to Present Clinical and Preclinical Data at the AD/PD(TM) 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases (Yahoo News) - "IRLAB Therapeutics AB...today announced that the company will present two abstracts at the scientific conference AD/PD 2024: 18th International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders in Lisbon, Portugal, on March 5-9, 2024."

Clinical protocol • Preclinical • CNS Disorders • Parkinson's Disease

PRECLINICAL IN VIVO CHARACTERIZATION OF IRL1117; A NOVEL DOPAMINE D1/D2 AGONIST FOR THE TREATMENT OF PARKINSON'S DISEASE (ADPD 2024) - "In conclusion, the data show that chronic treatment of 6-OHDA-lesioned rats with IRL1117 results in a robust effect on motor function without the simultaneous development of treatment-induced dyskinesias or the development of D1-mediated tachyphylaxis. Consequently, IRL1117 may constitute a novel chemical entity for once-daily treatment of the motor symptoms in Parkinson's disease, providing robust efficacy without the development of treatment-induced dyskinesia."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

IRLAB updates on portfolio development milestones (Market Screener) - "IRLAB Therapeutics AB...today announced that the company has assessed the operational priorities for 2023....This will not impact the priority of the ongoing Phase IIb study of pirepemat in PD-Falls. The preclinical programs will proceed according to their respective plans; IRL757 will proceed to be Phase I ready by year-end 2023, IRL942 will be Phase I ready in H1 2024 and P003 candidate IRL1117 is just initiating its preclinical program with in-house R&D activities during 2023. The analysis of the completed Phase IIb study of mesdopetam continues, and it is anticipated that further data will be presented during H1 2023. The ongoing Phase IIb study of pirepemat...is active and progressing to plan with 28 of 39 planned sites in five European countries. Patient recruitment is slower than anticipated, and actions are ongoing to address this. The updated estimates predict the study will be fully recruited by the year-end 2023 with top-line results in H1 2024."

Enrollment status • New P1 trial • P2b data • Preclinical • CNS Disorders • Cognitive Disorders • Parkinson's Disease

IRLAB Nominates IRL1117 As Drug Candidate from The P003 Project to Develop a Novel Treatment for Parkinson’s Disease (BioSpace) - "IRLAB Therapeutics AB...announced that a drug candidate has been nominated from the P003 research project. The drug candidate, IRL1117, will be developed as a once-daily oral treatment for the hallmark symptoms of Parkinson's without inducing the troublesome complications caused by today's mainstay anti-Parkinson's levodopa treatments. Initiation of development towards clinical studies has commenced and IRL1117 is expected to start Phase I studies in 2024....By comparison, IRL1117 offers a clearly differentiating alternative being orally available, potent and displaying a long-duration anti-parkinsonian efficacy without inducing the troublesome complications during long-term treatment."

New P1 trial • Pipeline update • CNS Disorders • Parkinson's Disease